Article Information
vol. 17 no. 4
Published By
Print ISSN
Online ISSN
History
- Received July 15, 2021
- Accepted July 27, 2021
- Published online December 7, 2021.
Copyright & Usage
Copyright ©ERS 2021 Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
Author Information
- 1Queens University Belfast School of Medicine Dentistry and Biomedical Sciences, Belfast, UK
- 2Alder Hey Children's NHS Foundation Trust, Liverpool, UK
- 3Dept of Paediatric Respiratory and Sleep Medicine, Royal Hospital for Children and Young People, Edinburgh, UK
- 4Department of Child Life and Health, University of Edinburgh, Edinburgh, UK
- 5Division of Child Health, University of Liverpool, Liverpool, UK
- 6Joint senior authors
- iansinha{at}liverpool.ac.uk @wheezylikesund1 @williams_t_c
Article usage
Altmetrics
Vol 17 Issue 4
Table of Contents
Palivizumab immunoprophylaxis for infants with BPD has medium- and long-term benefits: myth or maxim?
Jump To
- Article
- Abstract
- Respiratory consequences of preterm birth
- Babies with BPD are given palivizumab to prevent severe bronchiolitis
- Does RSV bronchiolitis increase the risk of respiratory illness through the life course?
- Does palivizumab reduce the risk of respiratory illness in childhood and adulthood?
- Summary and future directions
- Footnotes
- References
- Info & Metrics